Hyperacute GVHD: risk factors, outcomes, and clinical implications - PubMed (original) (raw)
Clinical Trial
. 2007 Apr 1;109(7):2751-8.
doi: 10.1182/blood-2006-07-034348.
Marcos de Lima, Sergio Giralt, Borje Andersson, Issa F Khouri, Chitra Hosing, Shubhra Ghosh, Joyce Neumann, Yvonne Hsu, Jorge De Jesus, Muzaffar H Qazilbash, Richard E Champlin, Daniel R Couriel
Affiliations
- PMID: 17138825
- DOI: 10.1182/blood-2006-07-034348
Free article
Clinical Trial
Hyperacute GVHD: risk factors, outcomes, and clinical implications
Rima M Saliba et al. Blood. 2007.
Free article
Abstract
Acute graft-versus-host disease (GVHD) is a major limiting factor in allogeneic hematopoietic stem cell transplantation (HSCT), and the timing of acute GVHD may affect patient outcomes. We evaluated the incidence, risk factors, clinical manifestations, and outcomes of hyperacute GVHD, defined as that occurring within 14 days after transplantation, among 809 consecutive HSCTs at the University of Texas M.D. Anderson Cancer Center. Of 265 patients with grade II-IV acute GVHD, 27% had biopsy-proven hyperacute GVHD. Skin involvement was significantly more common (88% versus 44%) and more severe (stage III-IV, 88% versus 66%) in the hyperacute group compared with acute GVHD diagnosed after day 14. On multivariate analysis, significant risk factors for hyperacute GVHD included a mismatched related or matched unrelated donor, a myeloablative conditioning regimen, more than 5 prior chemotherapy regimens, and donor-recipient sex mismatch. Hyperacute GVHD was associated with a significantly lower response rate to first-line therapy and a higher rate of nonrelapse mortality in patients with a mismatched related or matched unrelated donor graft. In conclusion, hyperacute GVHD accounts for a substantial proportion of grade II-IV acute GVHD after HSCT. Patients at high risk or with a diagnosis of hyperacute GVHD should be included in clinical studies.
Similar articles
- Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM, Kornblit B, Storer BE, Olesen G, Maris MB, Langston AA, Gutman JA, Petersen SL, Chauncey TR, Bethge WA, Pulsipher MA, Woolfrey AE, Mielcarek M, Martin PJ, Appelbaum FR, Flowers MED, Maloney DG, Storb R. Sandmaier BM, et al. Lancet Haematol. 2019 Aug;6(8):e409-e418. doi: 10.1016/S2352-3026(19)30088-2. Epub 2019 Jun 24. Lancet Haematol. 2019. PMID: 31248843 Free PMC article. Clinical Trial. - Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems.
MacMillan ML, Weisdorf DJ, Wagner JE, DeFor TE, Burns LJ, Ramsay NK, Davies SM, Blazar BR. MacMillan ML, et al. Biol Blood Marrow Transplant. 2002;8(7):387-94. doi: 10.1053/bbmt.2002.v8.pm12171485. Biol Blood Marrow Transplant. 2002. PMID: 12171485 - Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
Ji YS, Lee MS, Min CW, Park SK, Kim SH, Yun J, Kim HJ, Kim KH, Kim CK, Lee KT, Won JH, Hong DS. Ji YS, et al. Korean J Intern Med. 2016 Jul;31(4):750-61. doi: 10.3904/kjim.2015.234. Epub 2016 Mar 28. Korean J Intern Med. 2016. PMID: 27017944 Free PMC article. - Acute graft versus host disease.
Jacobsohn DA, Vogelsang GB. Jacobsohn DA, et al. Orphanet J Rare Dis. 2007 Sep 4;2:35. doi: 10.1186/1750-1172-2-35. Orphanet J Rare Dis. 2007. PMID: 17784964 Free PMC article. Review.
Cited by
- Approach to the Atypical Wound.
Becker SL, Kody S, Fett NM, Hines A, Alavi A, Ortega-Loayza AG. Becker SL, et al. Am J Clin Dermatol. 2024 Jul;25(4):559-584. doi: 10.1007/s40257-024-00865-0. Epub 2024 May 14. Am J Clin Dermatol. 2024. PMID: 38744780 Review. - Acute graft versus host disease 1976-2020: reduced incidence and predictive factors.
Di Francesco A, Raiola AM, Dominietto A, Di Grazia C, Gualandi F, Van Lint MT, Bregante S, Chiusolo P, Laurenti L, Sora F, Giammarco S, Metafuni E, Fresa A, Sica S, Angelucci E, Bacigalupo A. Di Francesco A, et al. Front Med (Lausanne). 2024 Jan 24;10:1320692. doi: 10.3389/fmed.2023.1320692. eCollection 2023. Front Med (Lausanne). 2024. PMID: 38327272 Free PMC article. - Understanding and treatment of cutaneous graft-versus-host-disease.
Hong J, Fraebel J, Yang Y, Tkacyk E, Kitko C, Kim TK. Hong J, et al. Bone Marrow Transplant. 2023 Dec;58(12):1298-1313. doi: 10.1038/s41409-023-02109-x. Epub 2023 Sep 20. Bone Marrow Transplant. 2023. PMID: 37730800 Review. - Hyperacute Graft-Versus-Host Disease of the Skin following Allogeneic Stem Cell Transplantation: A Paediatric Case Series.
Mahabal GD, George L, Peter D, Thomas M, George B, Mathews V, Abraham A, Srivastava A, Pulimood S. Mahabal GD, et al. Indian J Dermatol. 2023 Jan-Feb;68(1):73-77. doi: 10.4103/ijd.ijd_503_22. Indian J Dermatol. 2023. PMID: 37151270 Free PMC article. - Higher Starting Dose of Ciclosporin Optimized Therapeutic Levels in Patients Receiving Phenytoin for Busulfan-induced Seizure Prophylaxis.
Ho YS, Chong MF, Ng VC, Ho A, Ng HY. Ho YS, et al. Blood Cell Ther. 2021 Aug 25;4(3):58-64. doi: 10.31547/bct-2020-022. eCollection 2021 Aug 25. Blood Cell Ther. 2021. PMID: 36711059 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources